Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Hold” Rating by Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Several other analysts have also issued reports on REGN. Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Guggenheim increased their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $784.77.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $741.45 on Friday. The firm has a market capitalization of $77.93 billion, a P/E ratio of 17.76, a price-to-earnings-growth ratio of 1.95 and a beta of 0.39. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $758.39 and its two-hundred day moving average price is $649.85. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $12.07 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. WPG Advisers LLC increased its stake in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $31,000. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. Finally, Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $34,000. 83.31% of the stock is currently owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates (qtrly revenue $3.88B; EPS $11.44 vs. consensus ~$10.74), helped by Dupixent and Eylea HD sales — a near-term fundamental driver supporting the stock. GlobeNewswire – Q4 Results
• Positive Sentiment: Board raised the quarterly dividend to $0.94 (a ~6.8% increase vs. prior $0.88), signaling confidence in cash flow and making the stock slightly more attractive to income-focused investors.
• Positive Sentiment: Analyst optimism persists — Raymond James reiterated a Buy and set an $870 target; Evercore/ISI and others have also lifted targets, which can support demand on dips. TipRanks – Raymond James
• Positive Sentiment: Pipeline update: management highlighted an experimental obesity drug with added cholesterol-lowering benefits that could differentiate it in a crowded market — a potential medium-term growth driver. Reuters – Obesity drug story
• Neutral Sentiment: Full earnings materials and the Q4 earnings call transcript are available for deeper detail — useful for investors who want guidance commentary and pipeline timing. Seeking Alpha – Call Transcript
• Negative Sentiment: Despite the beats, EPS declined year-over-year (from $12.07 to $11.44) as higher expenses weighed on profitability — a headline that likely pressured sentiment. Reuters – Profit beat but EPS down YoY
• Negative Sentiment: Core Eylea weakness and investor concerns about sustainability of growth prompted some sell-side caution and profit-taking even after the beat, which helps explain the share decline today. MSN – Why shares fell

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.